Current therapeutic approaches to diffuse grade II and III gliomas

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Cancer Classification

Background:

• The 2016 WHO classification redefined diffuse glioma diagnosis by integrating molecular features with histology.
• Diffuse gliomas, particularly WHO grade II and III (lower-grade gliomas), exhibit significant heterogeneity in malignant potential.
• Molecular profiling is now indispensable for accurate classification, treatment planning, and identifying candidates for targeted therapies.

Purpose of the Study:

• To review advancements in classifying WHO grade II and III gliomas.
• To synthesize current treatment strategies based on molecular profiles.
• To explore future directions for targeted therapies in lower-grade gliomas.

Main Methods:

• Literature review of recent advances in glioma classification and treatment.
• Synthesis of data on molecular profiling's role in diagnosis and prognosis.
• Analysis of current treatment paradigms and emerging targeted therapies.

Main Results:

• Integrated diagnoses combining molecular and histological data are standard for diffuse gliomas.
• Molecular profiles provide critical prognostic stratification for lower-grade gliomas.
• Treatment decisions for lower-grade gliomas are increasingly guided by molecular findings, WHO grade, and patient status.

Conclusions:

• The 2016 WHO classification has revolutionized diffuse glioma diagnosis and management.
• Molecular profiling is essential for personalized treatment strategies and improved outcomes in lower-grade gliomas.
• Ongoing research focuses on novel targeted therapies, promising future advancements in neuro-oncology.